Sernova Announces Appointment of Ross Haghighat as Chair of the Board and a Change of Name to Sernova Biotherapeutics
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) has appointed Ross Haghighat as Chair of the Board. Haghighat brings over three decades of experience in founding, funding, and scaling technology ventures in healthcare, with expertise in driving successful innovations, strategic growth, and mergers and acquisitions in the biotechnology sector.
The company, which focuses on developing Cell Pouch bio-hybrid organ as a functional cure for Type 1 diabetes (T1D), also announced its corporate continuance from the Canada Business Corporations Act to the Business Corporations Act (British Columbia). Additionally, the company has changed its name from Sernova Corp. to Sernova Biotherapeutics Inc., while maintaining its existing ticker symbols.
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) ha nominato Ross Haghighat come Presidente del Consiglio. Haghighat porta con sé oltre tre decenni di esperienza nella fondazione, finanziamento e scalabilità di iniziative tecnologiche nel settore sanitario, con competenze nella guida di innovazioni di successo, crescita strategica e fusioni e acquisizioni nel settore biotecnologico.
L'azienda, che si concentra sullo sviluppo del Cell Pouch, un organo bio-ibrido funzionale come cura per il diabete di tipo 1 (T1D), ha anche annunciato la sua continuazione aziendale dalla Legge sulle Corporazioni dell'Canada alla Legge sulle Corporazioni (Columbia Britannica). Inoltre, l'azienda ha cambiato il proprio nome da Sernova Corp. a Sernova Biotherapeutics Inc., mantenendo i propri simboli di borsa esistenti.
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) ha nombrado a Ross Haghighat como Presidente de la Junta. Haghighat aporta más de tres décadas de experiencia en la fundación, financiación y escalado de empresas tecnológicas en el sector de la salud, con experiencia en la promoción de innovaciones exitosas, crecimiento estratégico y fusiones y adquisiciones en el sector de biotecnología.
La empresa, que se centra en el desarrollo del Cell Pouch, un órgano bio-híbrido funcional como cura para la diabetes tipo 1 (T1D), también ha anunciado su continuidad corporativa de la Ley de Corporaciones Comerciales de Canadá a la Ley de Corporaciones Comerciales (Columbia Británica). Además, la empresa ha cambiado su nombre de Sernova Corp. a Sernova Biotherapeutics Inc., manteniendo sus símbolos bursátiles existentes.
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF)가 Ross Haghighat를 이사회 의장으로 임명했습니다. Haghighat는 헬스케어 기술 기업의 설립, 자금 조달 및 확장에 대한 30년 이상의 경험을 가지고 있으며, 생명공학 분야에서 성공적인 혁신, 전략적 성장, 인수 및 합병을 이끌어내는 전문성을 보유하고 있습니다.
이 회사는 제1형 당뇨병(T1D)의 기능적 치료제로서 Cell Pouch 바이오 하이브리드 장기의 개발에 중점을 두고 있으며, 캐나다 기업법에서 브리티시컬럼비아 기업법으로의 법적 지위를 변경했다고 발표했습니다. 또한, 회사는 이름을 Sernova Corp.에서 Sernova Biotherapeutics Inc.로 변경했으며, 기존의 주식 기호는 유지하고 있습니다.
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) a nommé Ross Haghighat comme Président du Conseil. Haghighat apporte plus de trois décennies d'expérience dans la création, le financement et l'expansion d'entreprises technologiques dans le secteur de la santé, avec une expertise dans la conduite d'innovations réussies, la croissance stratégique et les fusions-acquisitions dans le secteur biotechnologique.
L'entreprise, qui se concentre sur le développement du Cell Pouch, un organe bio-hybride fonctionnel comme traitement du diabète de type 1 (T1D), a également annoncé sa continuité d'entreprise de la Loi canadienne sur les sociétés à la Loi sur les sociétés (Colombie-Britannique). De plus, l'entreprise a changé son nom de Sernova Corp. à Sernova Biotherapeutics Inc., tout en maintenant ses symboles boursiers existants.
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) hat Ross Haghighat als Vorsitzenden des Vorstands ernannt. Haghighat bringt über drei Jahrzehnte Erfahrung in der Gründung, Finanzierung und Skalierung von Technologieunternehmen im Gesundheitsbereich mit, sowie Expertise in der erfolgreichen Umsetzung von Innovationen, strategischem Wachstum und Fusionen und Übernahmen im Biotechnologiesektor.
Das Unternehmen, das sich auf die Entwicklung des Cell Pouch bio-hybrid Organs als funktionelle Heilung für Typ-1-Diabetes (T1D) konzentriert, gab außerdem bekannt, dass es von dem kanadischen Unternehmensgesetz auf das Unternehmensgesetz (British Columbia) umgewandelt wurde. Darüber hinaus hat das Unternehmen seinen Namen von Sernova Corp. zu Sernova Biotherapeutics Inc. geändert, während es seine bestehenden Börsensymbole beibehält.
- Appointment of experienced chairman with proven track record in biotech scaling and M&A
- Strategic leadership enhancement to support company's development of T1D treatment
- None.
LONDON, Ontario and BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for Type 1 diabetes (T1D), today announced the appointment of Ross Haghighat as Chair of the Board. With a proven track record in driving successful innovations, strategic growth and mergers and acquisitions in the biotechnology and life sciences sectors, Mr. Haghighat brings a wealth of financing and deal experience to Sernova’s Board and leadership team.
Jonathan Rigby, President and CEO of Sernova, stated, “We are thrilled to welcome Ross Haghighat as our new Chair of the Board. His deep industry knowledge and visionary leadership make him the perfect fit to guide Sernova as we advance our pipeline of transformative therapies. His appointment underscores our commitment to fulfilling our mission of bringing solutions to patients in need.”
Mr. Haghighat has over three decades of experience in founding, funding, and scaling technology ventures in healthcare, an asset that will support Sernova’s strategic direction and innovation objectives. He is known for his long-term strategic insights and the execution thereof, as evidenced in successfully driving multiple companies to achieve significant milestones and growth.
Commenting on his appointment, Mr. Haghighat remarked, “I am honored to join Sernova and support its journey toward approval of its Cell Pouch bio-hybrid organ as a functional cure for T1D. The company’s pioneering work in cell therapy is truly inspiring. I look forward to working with Jonathan, the Board, and the entire team to advance Sernova’s mission and deliver on our goals.”
Sernova’s Board of Directors expressed unanimous support for Mr. Haghighat’s appointment.
The Company is also pleased to report that it will complete the continuance of its corporate jurisdiction into British Columbia this week and the Company will become a corporation existing under the Business Corporations Act (British Columbia). The continuance of the Company’s corporate jurisdiction (which was formerly under the Canada Business Corporations Act) was approved by a special resolution of shareholders at the Company's annual and special general meeting held on January 10, 2025.
In connection with the continuance and to better communicate the nature of the business, the Company has changed its name from Sernova Corp. to Sernova Biotherapeutics Inc. No changes are expected in the Company’s ticker symbols.
ABOUT SERNOVA BIOTHERAPEUTICS
Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on Type 1 diabetes and thyroid disorders.
FOR FURTHER INFORMATION, PLEASE CONTACT:
David Burke VP, Investor Relations (917) 751-5713 Email: David.Burke@sernova.com Website: https://sernova.com/
The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.
FORWARD-LOOKING INFORMATION
This press release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this press release include our belief that our technology could lead to a functional cure for T1D. With respect to the forward-looking statements contained in this press release, Sernova has made numerous assumptions regarding, among other things: the company’s ability to secure additional financing on reasonable terms, or at all; and the ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch, including the timing and results of those trials. A more complete discussion of the risks and uncertainties facing Sernova appears in Sernova’s Annual Information Form for the year ended October 31, 2023 filed with Canadian securities authorities and available at www.sedarplus.ca, as updated by Sernova’s continuous disclosure filings, which are available at www.sedarplus.ca. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Sernova disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
FAQ
What is the significance of Ross Haghighat's appointment as Chair of the Board for SEOVF?
Why did Sernova (SEOVF) change its name to Sernova Biotherapeutics in January 2024?
What regulatory changes did SEOVF undergo in January 2024?
Will SEOVF's ticker symbols change following the corporate restructuring?
